Comparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the Community

Diabetes Technology and Therapeutics

Volumn 17, Issue 9, 2015, Pages 649-656

  Chan, Christine L ^a   Taki, Iman ^b   Dong, Fran ^b   Hoffman, Michelle ^b   Norris, Jill M ^c   Klingensmith, Georgeanna ^b   Rewers, Marian J ^b   Steck, Andrea K ^b  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

^c Food Science and Human Nutrition   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADOLESCENT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHILD; COMPARATIVE STUDY; DISEASE DURATION; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; METABOLIC PARAMETERS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ANALYSIS; AUTOIMMUNITY; BLOOD; BLOOD GLUCOSE MONITORING; DIABETES MELLITUS, TYPE 1; DIET RESTRICTION; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; MASS SCREENING; ONSET AGE; PROCEDURES; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; AGE OF ONSET; AUTOIMMUNITY; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; C-PEPTIDE; CASE-CONTROL STUDIES; CHILD; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; EARLY DIAGNOSIS; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MASS SCREENING; PROSPECTIVE STUDIES;

EID: 84940642928     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2015.0029     Document Type: Article

References (28)

1. Barker JM, Barriga KJ, Yu L, et al.: Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004;89:3896-3902.
2. The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann N Y Acad Sci 2008;1150:1-13.
3. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al.: The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 2009;10:97-104.
4. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al.: Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013;309:2473-2479.
5. Barker JM, Goehrig SH, Barriga K, et al.: Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 2004;27:1399-1404.
6. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al.: Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192.
7. The Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med 1998;128:517-523.
8. The DCCT Research Group: Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987;65:30-36.
9. Lachin JM, McGee P, Palmer JP, et al.: Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014; 63:739-748.
10. Palmer JP: C-peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev 2009;25:325-328.
11. Greenbaum CJ, Beam CA, Boulware D, et al.: Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 Diabetes TrialNet data. Diabetes 2012;61:2066-2073.
12. Palmer JP, Fleming GA, Greenbaum CJ, et al.: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264.
13. Rewers M, Bugawan TL, Norris JM, et al.: Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 1996;39:807-812.
14. Mortensen HB, Hougaard P, Swift P, et al.: New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 2009;32:1384-1390.
15. Schabenberger O, Pierce FJ: Contemporary Statistical Models for the Plant and Soil Sciences. Boca Raton, FL: CRC Press, 2002.
16. Atkinson MA, Eisenbarth GS: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-229.
17. Torn C, Landin-Olsson M, Lernmark A, et al.: Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 2000;85:4619-4623.
18. Petrone A, Galgani A, Spoletini M, et al.: Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes Metab Res Rev 2005;21:271-275.
19. Barker A, Lauria A, Schloot N, et al.: Age-dependent decline of beta-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diabetes Obes Metab 2014;16:262-267.
20. Greenbaum CJ, Anderson AM, Dolan LM, et al.: Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care 2009;32:1839-1844.
21. Sosenko JM, Palmer JP, Greenbaum CJ, et al.: Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643-649.
22. Steffes MW, Sibley S, Jackson M, et al.: Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003;26:832-836.
23. Buckingham B, Beck RW, Ruedy KJ, et al.: Effectiveness of early intensive therapy on beta-cell preservation in type 1 diabetes. Diabetes Care 2013;36:4030-4035.
24. Cook JJ, Hudson I, Harrison LC, et al.: Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 1989;38:779-783.
25. The Canadian-European Randomized Control Trial Group: Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988;37:1574-1582.
26. Herold KC, Hagopian W, Auger JA, et al.: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698.
27. Herold KC, Gitelman SE, Masharani U, et al.: A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-1769.
28. Brown RJ, Sinaii N, Rother KI: Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care 2008;31:1403-1404.